Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

REPOST (Now with less picking on Craig!) I

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153832
(Total Views: 533)
Posted On: 10/05/2023 10:33:52 AM
Posted By: Respert24
REPOST

(Now with less picking on Craig!)

I asked ChatGPT if AI will be able to replace human trials for investigational drug approvals in the future. Here is what she* said.

*Remember when Dishwalla sung about god being a woman in a way that you just knew meant they were trying to be far deeper than they were? Yeah, uh, me neither.

ChatGPT Says:


As of my last knowledge update in September 2021, AI has made significant strides in drug discovery and development, but completely replacing human trials for investigational drug approvals is a complex and multifaceted challenge. Here are some factors to consider:

1. Complexity of Human Biology: Human bodies are incredibly complex, and the interactions between drugs and our physiology are intricate and varied. While AI can simulate some of these interactions in silico (in a computer), it is challenging to capture the full complexity of human biology in a virtual environment.

2. Safety and Efficacy: One of the primary goals of clinical trials is to determine the safety and efficacy of a drug in humans. This involves not only looking at how a drug interacts with the body, but also understanding its impact on different patient populations, potential side effects, and long-term effects. AI can assist in the early stages of drug development, but understanding these aspects requires real-world trials.

3. Unforeseen Interactions: New drugs can have unforeseen interactions with existing medications, or with specific genetic or environmental factors. These interactions are difficult to predict using AI alone.

4. Regulatory Approval and Ethical Considerations: Regulatory bodies, such as the FDA in the United States, have established rigorous standards for drug approval. These standards are based on a wealth of historical evidence and prioritize patient safety. Moving from human trials to a solely AI-based system would require a major shift in global regulatory frameworks.

5. Patient Variability: Humans are highly variable. Factors like age, genetics, lifestyle, and environment can significantly impact how individuals respond to drugs. Clinical trials are designed to capture this variability.

6. Real-World Data Challenges: While AI can analyze large amounts of data, much of it comes from controlled clinical trial environments. Real-world data is messier and often harder to interpret. Incorporating this kind of data into a solely AI-driven approval process would be a significant challenge.

7. Ethical Considerations and Public Trust: There are ethical considerations surrounding the use of AI in healthcare. Patients and the public need to trust that new drugs have been thoroughly tested and are safe.

While AI is revolutionizing drug discovery by expediting the initial stages of identifying potential drug candidates, predicting their behavior, and even suggesting combinations, it is unlikely, at least in the foreseeable future, to fully replace human trials for investigational drug approvals. The gold standard of clinical trials serves a vital role in ensuring patient safety and drug efficacy. The future likely involves a synergistic relationship between AI and traditional clinical trials, with AI aiding in the design and optimization of trials.



Now that I've put that subject to bed, I also asked ChatGPT whether or not it thinks Cytodyn will have any catalysts hit this month.

It claimed it hasn't been updated in a couple years and can't predict the future, which is bullshit. I can't believe I'm not allowed to just hammer the keys on my laptop into questions that get immediately and accurately answered. What the fuck am I getting for the $1,000 I spent on this Lenovo laptop then?

Sticky keys?

That's it?

Bummer.

Oh wait, I do remember that there's one other thing I get with this laptop. Every month it will decide that it no longer has fingerprint recognition. Then after some updates it'll be like, Hey buddy, wanna use your fingerprint? I'm all ready for it. Which finger are you gonna use? Pointer? Nice call. Strong choice, the pointer. Now nestle that thing up on this tiny square and let's open your laptop. Mmm, I'm sure McAfee missed you while you were gone. Wanna scan some files together? Watch some black boxes needlessly flash on the screen for a nanosecond and never come back to explain why the hell you needed to see it? Maybe pop up an insufferable amount of reminders about what McAfee could do for you if you'd just let it? Why aren't you letting McAfee help you? McAfee can teach you many things, but McAfee won't beg. Come to Omaha with McAfee and let McAfee introduce you to some new experiences. Hey, where are you going? Reddit? Oh come on, it's a cesspool over there and they no longer let you give those little widget emoji things, I heard. Hey! Remember when you could buzz people on yahoo messenger? That was fun. A simple pleasure. Like making the dial up internet sounds back when you couldn't just connect in a millisecond, you had to wait for your computer to scream at you in various pitches for like ten seconds first. And you needed a CD at one point! Awww, CD's were the shit. I miss em. Even a Dishwalla album seemed cool when it was packaged in that unnecessarily sized rectangle package that only had the disc in the top half with the bottom half existing for no apparent reason.

I guess what I'm trying to say is buy low and sell high. Or, buy low then high, then chase it down and keep buying, and then say you're not going to buy any more but then buy more multiple times because it's so goddamn cheap right now. Then sit back and wait for the dominoes to start falling. But also buy more between now and then.


(10)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us